Sick Economics

CSBR

This emerging growth microcap has recently reached profitability along with impressive revenue gains. Champions Oncology, Inc. is making a name for itself by offering a wide range of research services to other pharmaceutical companies in the oncology field. Lately, the company has expanded into two promising new areas of growth; oncology research software, and new drug development. With the advent of precision cancer medicine and the explosion of new approaches to cancer treatment, Champions is well positioned to become a pillar of the oncology community.

Click On Chart To Expand

MESO

This Australian company, listed on the NASDAQ stock exchange, seeks to treat a wide range of diseases through the creation of new kinds of cellular therapies. MESO currently has three phase III products in development. On August 14th, 2020, an FDA advisory committee voted 9-1 to recommend approval of Remestemcel-L as a novel treatment for graft vrs host disease in children. This vote puts Meso on track to launch its first FDA approved product in 2021. The company is also in advanced testing of new cellular therapies for severe Covid-19, lower back pain, and cardiovascular disease.

Click On Chart To Expand

MORF

Morphic Holding, Inc, is pioneering therapies that focus on integrins, a category of proteins that play a role in many chronic diseases of the autoimmune, cardiovascular and metabolic systems. The small biotech has recently expanded on a partnership with a Pharma Giant (ABBV). AbbVie has chosen to exercise a license option to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. We’ll be keeping a close eye on MORF over the coming months and years. If all goes well, MORF has a massive potential upside.

Click On Chart To Expand